Table 5 Lipids, apoAI, apoB level and lipid and lipoprotein ratios in the control group and patients with apoAI ≥150 mg/dL, apoAI ≤150 mg/dL and all patients with CAP, median (min- max)

TG (mmol/L)

1.07(0.70–1.94)

1.27(0.58–1.84)

1.45(0.65–4.26)

1.33(0.58–4.26)

TC (mmol/L)

4.92(4.35–5.69)

5.49(4.19–7.20)

5.28(3.80–7.40)

5.38(3.80–7.40)

LDL-C (mmol/L)

3.15(2.20–3.62)

4.04(2.20–4.71)

3.72(2.14–5.23)

3.78(2.14–5.23)

HDL-C (mmol/L)

1.42(1.13–2.40)

1.52(1.19–2.07)

1.08(0.49–1.50)*,***

1.16(0.49–2.07)

nHDL-C (mmol/L)

3.62(2.53–4.19)

4.06(2.53–5.23)

4.35-(2.64–6.21)

3.93(2.64–6.21)

apoAI (g/L)

1680(1500–2030)

1740(1500–2350)

1340(790–1480)*,***

1440(790–2350)

apoB (g/L)

880(620–1060)

760(520–1280)

86(0500–1490)

870(500–1490)

TC/HDL-C

3.45(2.17–4.45)

3.58(2.56–4.82)

4.92(2.68–9.27)*

4.63(2.56–9.27)*

LDL/HDL-C

2.22(1.11–3.72)

2.64(1.35–3.54)

3.50(1.80–9.53)*

3.24(1.35–9.53)*

TG/HDL-C

1.72(1.0–3.2)

1.91(0.72–3.26)

3.09(1.07–11.82)*

2.56(0.72–11.82)*

HDL-C/apoAI

0.33(0.32–0.47)

0.33(0.27–0.51)

0.31(0.16–0.66)

0.31(0.16–0.66)

apoAI/apoB

1.89(1.17–3.27)

2.28(1.36–3.27)

1.56(0.70–2.55)*

1.65(0.70–3.17)